Curis - News - 500 Beiträge pro Seite
eröffnet am 14.11.00 11:33:30 von
neuester Beitrag 01.04.01 18:47:36 von
neuester Beitrag 01.04.01 18:47:36 von
Beiträge: 30
ID: 299.786
ID: 299.786
Aufrufe heute: 0
Gesamt: 1.837
Gesamt: 1.837
Aktive User: 0
ISIN: US2312693094 · WKN: A3ETJD · Symbol: CUS0
9,9000
EUR
-4,81 %
-0,5000 EUR
Letzter Kurs 29.05.24 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,9600 | +41,71 | |
| 5,3000 | +28,64 | |
| 1,3000 | +26,21 | |
| 5,3800 | +14,96 | |
| 1,2400 | +12,73 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,4200 | -18,15 | |
| 9,6000 | -18,64 | |
| 2,0550 | -20,35 | |
| 1,4600 | -24,56 | |
| 1,7000 | -31,17 |
Feedback
Hier das neueste von Curis, setze gleich eine Übersetzung rein.
Curis, Inc. (ticker: CRIS, exchange: NASDAQ) News Release - 11/13/2000
--------------------------------------------------------------------------------
Hedgehog Protein Accelerates Nerve Regeneration in Pre-clinical Models; Increased Levels of Protein Stimulate Nerve Recovery
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 13, 2000--Findings presented last week at the Society for Neuroscience by a team of researchers from Curis, Inc. (NASDAQ: CRIS) led by Drs. Karen Allendoerfer and Carmen Pepicelli show that the Hedgehog pathway is activated following injury to peripheral nerves in pre-clinical models and plays a key role in the nerve recovery process.
These findings suggest that therapeutics designed to stimulate this system may be of significant value in treating disorders associated with trauma and neuropathies, which represent a total market in excess of $1 billion.
The increased levels of Hedgehog proteins and other proteins under their control seen after nerve injury indicates that the body`s attempt to restore nerve function is focused on the activation of these molecules.
The Curis findings are based on examining changes that occur in adult nerves in pre-clinical models following traumatic nerve injury. Soon after nerve damage occurs, levels of hedgehog protein increase as do other associated proteins, including essential gene regulatory proteins. Researchers found that blocking these changes impairs the nerve`s ability to recover function whereas stimulating these changes by treating with a derivative of the recombinant hedgehog protein markedly improves the nerve`s ability to repair itself.
These results complement the studies recently communicated by Dr. David Tomlinson of the University of Manchester at the Society for Diabetic Neuropathy`s Fifth Annual Diabetic Neuropathy Satellite Meeting that describe the ability of exogenously administered hedgehog protein to improve nerve function in pre-clinical models of diabetic neuropathy.
"Curis continues to generate pre-clinical data supporting the efficacy and safety of Hedgehog-based therapeutics in neurological disorders," said Doros Platika, M.D., president and chief executive officer of Curis. "We anticipate that these studies will serve as the basis for future clinical trials and add to the already extensive Curis pipeline of regenerative products."
Hedgehog proteins have previously been shown to play a role in the embryonic development of the central and peripheral nervous systems. The objective of ongoing research at Curis in the areas of peripheral and diabetic neuropathies is the activation of the Hedgehog pathway to promote the repair and restoration of normal function in the nervous system that has been compromised by disease or injury. The research and development of innovative therapies by Curis to treat a variety of disorders is focused upon recreating the conditions and redirecting key inducing molecules such as those involved in the Hedgehog pathway that control the normal growth of cells and tissues.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. The completion of a successful pre-clinical trial does not mean the Company will be able to successfully commercialize the product. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000 and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2000.
--30--es/bos*
CONTACT: Curis, Inc.
William B. Boni
(617) 876-0086, ext. 6506
or
Curis, Inc.
Cynthia Clayton
(617) 876-0086, ext. 6641
or
Noonan / Russo Communications:
Anthony Russo
(212) 696-4455, ext. 202
or
Noonan / Russo Communications:
Renee Connolly
(212) 696-4455, ext. 227
Curis, Inc. (ticker: CRIS, exchange: NASDAQ) News Release - 11/13/2000
--------------------------------------------------------------------------------
Hedgehog Protein Accelerates Nerve Regeneration in Pre-clinical Models; Increased Levels of Protein Stimulate Nerve Recovery
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 13, 2000--Findings presented last week at the Society for Neuroscience by a team of researchers from Curis, Inc. (NASDAQ: CRIS) led by Drs. Karen Allendoerfer and Carmen Pepicelli show that the Hedgehog pathway is activated following injury to peripheral nerves in pre-clinical models and plays a key role in the nerve recovery process.
These findings suggest that therapeutics designed to stimulate this system may be of significant value in treating disorders associated with trauma and neuropathies, which represent a total market in excess of $1 billion.
The increased levels of Hedgehog proteins and other proteins under their control seen after nerve injury indicates that the body`s attempt to restore nerve function is focused on the activation of these molecules.
The Curis findings are based on examining changes that occur in adult nerves in pre-clinical models following traumatic nerve injury. Soon after nerve damage occurs, levels of hedgehog protein increase as do other associated proteins, including essential gene regulatory proteins. Researchers found that blocking these changes impairs the nerve`s ability to recover function whereas stimulating these changes by treating with a derivative of the recombinant hedgehog protein markedly improves the nerve`s ability to repair itself.
These results complement the studies recently communicated by Dr. David Tomlinson of the University of Manchester at the Society for Diabetic Neuropathy`s Fifth Annual Diabetic Neuropathy Satellite Meeting that describe the ability of exogenously administered hedgehog protein to improve nerve function in pre-clinical models of diabetic neuropathy.
"Curis continues to generate pre-clinical data supporting the efficacy and safety of Hedgehog-based therapeutics in neurological disorders," said Doros Platika, M.D., president and chief executive officer of Curis. "We anticipate that these studies will serve as the basis for future clinical trials and add to the already extensive Curis pipeline of regenerative products."
Hedgehog proteins have previously been shown to play a role in the embryonic development of the central and peripheral nervous systems. The objective of ongoing research at Curis in the areas of peripheral and diabetic neuropathies is the activation of the Hedgehog pathway to promote the repair and restoration of normal function in the nervous system that has been compromised by disease or injury. The research and development of innovative therapies by Curis to treat a variety of disorders is focused upon recreating the conditions and redirecting key inducing molecules such as those involved in the Hedgehog pathway that control the normal growth of cells and tissues.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. The completion of a successful pre-clinical trial does not mean the Company will be able to successfully commercialize the product. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000 and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2000.
--30--es/bos*
CONTACT: Curis, Inc.
William B. Boni
(617) 876-0086, ext. 6506
or
Curis, Inc.
Cynthia Clayton
(617) 876-0086, ext. 6641
or
Noonan / Russo Communications:
Anthony Russo
(212) 696-4455, ext. 202
or
Noonan / Russo Communications:
Renee Connolly
(212) 696-4455, ext. 227
Hier auszugsweise die Übersetzung ( leider über Babelfish, daher grammatikalisch etwas daneben).
Gruss
CC
Protein Hedgehog beschleunigt Nerv Regeneration in den Vor-klinischen Modellen; Erhöhte Stufen des Proteins regen Nerv Wiederanlauf an Cambridge, Mass. -- (BUSINESS WIRE) -- Nov.. 13, 2000 -- Entdeckungen stellten letzte Woche an der Gesellschaft für Neurologie durch ein Team der Forscher von Curis, Inc. dar (Nasdaq: CRIS) geführt durch Drs. Karen Allendoerfer und Erscheinen Carmen Pepicelli, daß die Bahn Hedgehog nach Verletzung der Zusatznerven in den vor-klinischen Modellen aktiviert und eine Schlüsselrolle im Nerv Wiederanlaufprozeß spielt wird. Diese Entdeckungen schlagen vor, daß die Therapeutik, die entworfen wird, um dieses System anzuregen, vom bedeutenden Wert in den behandelnden Störungen sein kann, die mit Trauma und neuropathies dazugehörig sind, die einen Gesamtmarkt über $1 Milliarde darstellen. Die erhöhten Stufen der Proteine Hedgehog und anderer Proteine unter ihrer Steuerung gesehen, nachdem Nerv Verletzung anzeigt, daß der Versuch des Körpers, Nerv Funktion wiederhzuerstellen auf die Aktivierung dieser Moleküle gerichtet wird. Die Entdeckungen Curis basieren auf Überprüfenänderungen, die in den Erwachsennerven in den vor-klinischen Modellen eintreten, die traumatischer Nerv Verletzung folgen. Bald, nachdem Nerv Beschädigung auftritt, Stufen der hedgehogproteinzunahme, wie andere dazugehörige Proteine, einschließlich der regelnden Proteine des wesentlichen Gens. Forscher fanden den, diese Änderungen zu blocken hindert die Fähigkeit des Nervs, Funktion, während das Anregen dieser Änderungen, indem es mit einer Ableitung des recombinant hedgehogproteins, wiederherzustellen behandelt deutlich die Fähigkeit des Nervs verbessert, sich zu reparieren. Diese Resultate nzen die Studien ergä, die vor kurzem vom Dr. David Tomlinson der Universität von Manchester an der Gesellschaft für Satellitensitzung der 5. jährlichen zuckerkranken Neuropathie der zuckerkranken Neuropathie mitgeteilt werden, die die Fähigkeit des exogen ausgeübten hedgehogproteins beschreiben, Nerv Funktion in den vor-klinischen Modellen der zuckerkranken Neuropathie zu verbessern.
Gruss
CC
Protein Hedgehog beschleunigt Nerv Regeneration in den Vor-klinischen Modellen; Erhöhte Stufen des Proteins regen Nerv Wiederanlauf an Cambridge, Mass. -- (BUSINESS WIRE) -- Nov.. 13, 2000 -- Entdeckungen stellten letzte Woche an der Gesellschaft für Neurologie durch ein Team der Forscher von Curis, Inc. dar (Nasdaq: CRIS) geführt durch Drs. Karen Allendoerfer und Erscheinen Carmen Pepicelli, daß die Bahn Hedgehog nach Verletzung der Zusatznerven in den vor-klinischen Modellen aktiviert und eine Schlüsselrolle im Nerv Wiederanlaufprozeß spielt wird. Diese Entdeckungen schlagen vor, daß die Therapeutik, die entworfen wird, um dieses System anzuregen, vom bedeutenden Wert in den behandelnden Störungen sein kann, die mit Trauma und neuropathies dazugehörig sind, die einen Gesamtmarkt über $1 Milliarde darstellen. Die erhöhten Stufen der Proteine Hedgehog und anderer Proteine unter ihrer Steuerung gesehen, nachdem Nerv Verletzung anzeigt, daß der Versuch des Körpers, Nerv Funktion wiederhzuerstellen auf die Aktivierung dieser Moleküle gerichtet wird. Die Entdeckungen Curis basieren auf Überprüfenänderungen, die in den Erwachsennerven in den vor-klinischen Modellen eintreten, die traumatischer Nerv Verletzung folgen. Bald, nachdem Nerv Beschädigung auftritt, Stufen der hedgehogproteinzunahme, wie andere dazugehörige Proteine, einschließlich der regelnden Proteine des wesentlichen Gens. Forscher fanden den, diese Änderungen zu blocken hindert die Fähigkeit des Nervs, Funktion, während das Anregen dieser Änderungen, indem es mit einer Ableitung des recombinant hedgehogproteins, wiederherzustellen behandelt deutlich die Fähigkeit des Nervs verbessert, sich zu reparieren. Diese Resultate nzen die Studien ergä, die vor kurzem vom Dr. David Tomlinson der Universität von Manchester an der Gesellschaft für Satellitensitzung der 5. jährlichen zuckerkranken Neuropathie der zuckerkranken Neuropathie mitgeteilt werden, die die Fähigkeit des exogen ausgeübten hedgehogproteins beschreiben, Nerv Funktion in den vor-klinischen Modellen der zuckerkranken Neuropathie zu verbessern.
Jetzt interessiert mich die Aktie auch langsam. Ist ja stark zurückgekommen, und alles was mit echter Nervenregeneration zu tun hat, läßt $-Zeichen in meinen Augen aufblitzen.
Ich werde mir mal das Ding näher anschauen.
Ich werde mir mal das Ding näher anschauen.
Heute soll durch die Firma Stryker eine europäische OP1-Präsentation stattfinden. Hat jemand schon Erkenntnisse hinsichtlich dieser Präsentation ?
P.S. 17.20 Uhr CRIS an der Nasdaq + 18,12 %
P.S. 17.20 Uhr CRIS an der Nasdaq + 18,12 %
Curis füllt die Kriegskasse
Curis Raises $46.8 Million in Private Placement of Common Stock
CAMBRIDGE, Mass.--(BW HealthWire)--Nov. 16, 2000--Curis, Inc. (NASDAQ: CRIS) today announced that it has raised $46.8 million in gross proceeds from the sale of 5.2 million shares of newly issued Curis common stock at a price of $9.00 per share. Prudential Vector Healthcare Group, a unit of Prudential Securities, acted as the placement agent for this transaction.
"In response to demand, we increased the number of shares to be sold in this placement from the original offering size," said Doros Platika, M.D., president and chief executive officer of Curis. "This transaction strengthens our financial position, almost doubling our total cash and investment balance to approximately $87 million on a pro forma basis as of September 30, 2000."
Total shares outstanding of Curis common stock following this transaction number approximately 31.3 million.
The Company plans to use the proceeds of the private placement to fund its ongoing research and development, capital expenditures, sales and marketing capability, potential acquisitions, working capital and general corporate purposes.
The Company intends to file with the Securities and Exchange Commission a resale registration statement on Form S-1 within 15 days of today relating to the privately placed shares, and the closing of the financing is conditioned upon the effectiveness of the registration statement. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. Any offering of Curis shares under the resale registration statement will be made only by means of a prospectus.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. The completion of a successful pre-clinical trial does not mean the Company will be able to successfully commercialize the product. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000 and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2000.
CONTACT: Curis, Inc.
William B. Boni
(617) 876-0086, ext. 6506
or
Cynthia Clayton
(617) 876-0086, ext. 6641
Curis Raises $46.8 Million in Private Placement of Common Stock
CAMBRIDGE, Mass.--(BW HealthWire)--Nov. 16, 2000--Curis, Inc. (NASDAQ: CRIS) today announced that it has raised $46.8 million in gross proceeds from the sale of 5.2 million shares of newly issued Curis common stock at a price of $9.00 per share. Prudential Vector Healthcare Group, a unit of Prudential Securities, acted as the placement agent for this transaction.
"In response to demand, we increased the number of shares to be sold in this placement from the original offering size," said Doros Platika, M.D., president and chief executive officer of Curis. "This transaction strengthens our financial position, almost doubling our total cash and investment balance to approximately $87 million on a pro forma basis as of September 30, 2000."
Total shares outstanding of Curis common stock following this transaction number approximately 31.3 million.
The Company plans to use the proceeds of the private placement to fund its ongoing research and development, capital expenditures, sales and marketing capability, potential acquisitions, working capital and general corporate purposes.
The Company intends to file with the Securities and Exchange Commission a resale registration statement on Form S-1 within 15 days of today relating to the privately placed shares, and the closing of the financing is conditioned upon the effectiveness of the registration statement. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. Any offering of Curis shares under the resale registration statement will be made only by means of a prospectus.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. The completion of a successful pre-clinical trial does not mean the Company will be able to successfully commercialize the product. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000 and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2000.
CONTACT: Curis, Inc.
William B. Boni
(617) 876-0086, ext. 6506
or
Cynthia Clayton
(617) 876-0086, ext. 6641
Trading Spotlight
Deutsche Übersetzung ( leider nur Babelfish - Grammatik ist mies, aber man kann sich zumindest ein genaueres Bild machen)
Curis hebt $46,8 Million in der Privatplazierung von Stammaktien an Geschäft Leitung November 16, 2000 9:30am CAMBRIDGE, Mass., Nov. 16, 2000 (BW HealthWire) -- Curis, Inc. (Nasdaq: CRIS) verkündete heute, daß es $46,8 Million in den groben Erträgen vom Verkauf von 5,2 Million Anteilen der eben herausgegebenen Stammaktien Curis zu einem Preis von $9,00 pro Anteil angehoben hat. Vernünftige Gruppe vektorHealthcare, eine Maßeinheit der vernünftigen Aktien, gedient als das Plazierung Mittel für diese Verhandlung. " in Erwiderung auf Nachfrage, erhöhten wir die Zahl den in dieser Plazierung von der ursprünglichen anbietengröße zu verkaufenden Anteilen, ", sagte Doros Platika, M.D., Präsident und Generaldirektor von Curis. " diese Verhandlung verstärkt unsere Finanzlage und fast verdoppelt unsere Gesamtbargeld- und Investitionabgleichung bis ungefähr $87 Million auf einer Proformagrundlage ab September 30, 2000. ", Die Gesamtausgegebenen Aktien von den Stammaktien Curis nach dieser Verhandlung numerieren ungefähr 31,3 Million. Die Firma plant, die Erträge der Privatplazierung zu verwenden, um seine fortwährende Forschung und Entwicklung, Kapitalaufwand, Verkäufe und Marketing-Fähigkeit, mögliche Datenerfassungen, Arbeitskapital und allgemeiner Gegenstand des Unternehmens zu finanzieren. Die Firma beabsichtigt, mit den Aktien und der Austauschkommission eine Weiterverkaufausrichtung Anweisung auf Formular S-1 innerhalb 15 Tage heutigen Tages in bezug auf die privat plazierten Anteile zu archivieren, und das Schließen der Finanzierung wird nach der Wirksamkeit der Ausrichtung Anweisung bedungen. Diese Aktien können möglicherweise nicht verkauft werden noch können die Angebote, kaufen werden angenommen vor der Zeit, daß die Ausrichtung Anweisung wirkungsvoll wird. Diese Nachrichten Freigabe setzt nicht ein Angebot fest, um zu verkaufen oder das Marketing eines zu kaufenden Angebots, noch gibt es jeden möglichen Verkauf dieser Aktien in irgendeinem Zustand, in dem solches Angebot, Marketing oder Verkauf vor der Ausrichtung oder der Qualifikation unter den Sicherheiten Gesetzen irgend solchen Zustandes ungesetzlich sein würden. Jeder möglicher Antrag der Anteile Curis unter der Weiterverkaufausrichtung Anweisung wird nur mittels eines Prospekts gebildet.
Curis hebt $46,8 Million in der Privatplazierung von Stammaktien an Geschäft Leitung November 16, 2000 9:30am CAMBRIDGE, Mass., Nov. 16, 2000 (BW HealthWire) -- Curis, Inc. (Nasdaq: CRIS) verkündete heute, daß es $46,8 Million in den groben Erträgen vom Verkauf von 5,2 Million Anteilen der eben herausgegebenen Stammaktien Curis zu einem Preis von $9,00 pro Anteil angehoben hat. Vernünftige Gruppe vektorHealthcare, eine Maßeinheit der vernünftigen Aktien, gedient als das Plazierung Mittel für diese Verhandlung. " in Erwiderung auf Nachfrage, erhöhten wir die Zahl den in dieser Plazierung von der ursprünglichen anbietengröße zu verkaufenden Anteilen, ", sagte Doros Platika, M.D., Präsident und Generaldirektor von Curis. " diese Verhandlung verstärkt unsere Finanzlage und fast verdoppelt unsere Gesamtbargeld- und Investitionabgleichung bis ungefähr $87 Million auf einer Proformagrundlage ab September 30, 2000. ", Die Gesamtausgegebenen Aktien von den Stammaktien Curis nach dieser Verhandlung numerieren ungefähr 31,3 Million. Die Firma plant, die Erträge der Privatplazierung zu verwenden, um seine fortwährende Forschung und Entwicklung, Kapitalaufwand, Verkäufe und Marketing-Fähigkeit, mögliche Datenerfassungen, Arbeitskapital und allgemeiner Gegenstand des Unternehmens zu finanzieren. Die Firma beabsichtigt, mit den Aktien und der Austauschkommission eine Weiterverkaufausrichtung Anweisung auf Formular S-1 innerhalb 15 Tage heutigen Tages in bezug auf die privat plazierten Anteile zu archivieren, und das Schließen der Finanzierung wird nach der Wirksamkeit der Ausrichtung Anweisung bedungen. Diese Aktien können möglicherweise nicht verkauft werden noch können die Angebote, kaufen werden angenommen vor der Zeit, daß die Ausrichtung Anweisung wirkungsvoll wird. Diese Nachrichten Freigabe setzt nicht ein Angebot fest, um zu verkaufen oder das Marketing eines zu kaufenden Angebots, noch gibt es jeden möglichen Verkauf dieser Aktien in irgendeinem Zustand, in dem solches Angebot, Marketing oder Verkauf vor der Ausrichtung oder der Qualifikation unter den Sicherheiten Gesetzen irgend solchen Zustandes ungesetzlich sein würden. Jeder möglicher Antrag der Anteile Curis unter der Weiterverkaufausrichtung Anweisung wird nur mittels eines Prospekts gebildet.
Paul Allen raises his stake in Curis
WASHINGTON, Nov 21 (Reuters) - Microsoft Corp. <MSFT.O> co-founder Paul Allen, one of the richest men in the world, raised his stake in medical technology firm Curis Inc. <CRIS.O> to 7.4 percent from 6.2 percent, according to a filing on Tuesday with the Securities and Exchange Commission.
The regulatory document showed that Allen`s Vulcan Ventures investment vehicle bought 750,000 common shares of Curis on Nov. 13 in a private transaction for $9 a share, raising its total holdings to 2,318,663 from 1,568,663 shares.
Curis shares were down 9/64 to $10-1/2 in afternoon Nasdaq trading. The shares of the Cambridge, Mass.-based company have hit a 52-week high of $27-4/16 and a low of $9-12/16.
Curis is developing products based on technologies in the emerging field of regenerative medicine, a new approach to healing that uses genes, proteins, antibodies and cells to repair organs and tissues. Allen holds the stake for investment purposes, his SEC filing said.
Through Vulcan, Allen also has investments in cable, telecommunications and other companies. In addition, he owns the Seattle Seahawks and the Portland Trailblazers sports teams.
((Peter Ramjug, Reuters SEC Desk, 202-898-8399))
REUTERS
na denn
wollen mir mal hoffen
gruß Steve de Ville
auf steigende Kurse
WASHINGTON, Nov 21 (Reuters) - Microsoft Corp. <MSFT.O> co-founder Paul Allen, one of the richest men in the world, raised his stake in medical technology firm Curis Inc. <CRIS.O> to 7.4 percent from 6.2 percent, according to a filing on Tuesday with the Securities and Exchange Commission.
The regulatory document showed that Allen`s Vulcan Ventures investment vehicle bought 750,000 common shares of Curis on Nov. 13 in a private transaction for $9 a share, raising its total holdings to 2,318,663 from 1,568,663 shares.
Curis shares were down 9/64 to $10-1/2 in afternoon Nasdaq trading. The shares of the Cambridge, Mass.-based company have hit a 52-week high of $27-4/16 and a low of $9-12/16.
Curis is developing products based on technologies in the emerging field of regenerative medicine, a new approach to healing that uses genes, proteins, antibodies and cells to repair organs and tissues. Allen holds the stake for investment purposes, his SEC filing said.
Through Vulcan, Allen also has investments in cable, telecommunications and other companies. In addition, he owns the Seattle Seahawks and the Portland Trailblazers sports teams.
((Peter Ramjug, Reuters SEC Desk, 202-898-8399))
REUTERS
na denn
wollen mir mal hoffen
gruß Steve de Ville
auf steigende Kurse
Curis nachbörslich auf 13 DollarAfter Hours Trade Reporting
Tuesday November 14 After Hours Most Active
After Hours
Last: $13 After Hours
Best Bid: $10.375 After Hours
High: $13.125
After Hours
Volume: 14,000 After Hours
Best Ask: $12.75 After Hours
Low: $13
After Hours
Time (ET) After Hours
Price After Hours
Share Volume
16.20 $ 13 100
16.16 $ 13 100
16.11 $ 13 400
16.10 $ 13 800
16.10 $ 13.125 1000
16.10 $ 13.125 1000
16.06 $ 13 600
16.02 $ 13 10000
gruß Steve de Ville auf steigende Kurse
denke mal übles Spiel mit uns Kleinanlegern
lassen den Kurs fallen um günstig einzusteigen
na ja jetzt wird der zug hoffentlich nach Norden fahren
Tuesday November 14 After Hours Most Active
After Hours
Last: $13 After Hours
Best Bid: $10.375 After Hours
High: $13.125
After Hours
Volume: 14,000 After Hours
Best Ask: $12.75 After Hours
Low: $13
After Hours
Time (ET) After Hours
Price After Hours
Share Volume
16.20 $ 13 100
16.16 $ 13 100
16.11 $ 13 400
16.10 $ 13 800
16.10 $ 13.125 1000
16.10 $ 13.125 1000
16.06 $ 13 600
16.02 $ 13 10000
gruß Steve de Ville
auf steigende Kurse denke mal übles Spiel mit uns Kleinanlegern
lassen den Kurs fallen um günstig einzusteigen
na ja jetzt wird der zug hoffentlich nach Norden fahren
hallo leute
tut mir leid
mein oberes posting bezüglich der nachbörslichen Steigerung
ist leider falsch
war mein Fehler hab nicht aufs Datum gesehen
und es wurde auch falsch angezeigt
trotzdem
wollen wir das beste hoffen und das tiefe Tal durchschreiten
gruß Steve de Ville auf steigende Kurse
tut mir leid
mein oberes posting bezüglich der nachbörslichen Steigerung
ist leider falsch
war mein Fehler hab nicht aufs Datum gesehen
und es wurde auch falsch angezeigt
trotzdem
wollen wir das beste hoffen und das tiefe Tal durchschreiten
gruß Steve de Ville
auf steigende Kurse
Hier die neuesten Curis - News. An dieser Stelle Dank an
@Westerheide aus dem Consors - Board, der hinsichtlich Curis immer am Ball ist. Ich stelle seinen Beitrag einfach mal ins Board und hoffe auf sein Einverständnis:
Auf der gestrigen Konferenz bei Robertson Stephens sagte Curis` CEO Platika, daß die Zulassung für OP-1 am Anfang nächsten Jahres erwartet wird (für Amerika!!!). Er schätze das jährliche Potential auf 1 Milliarde $. Ausserdem wird nächstes Jahr die Zulassung für Curis` 2. Produkt Chondrogel beantragt. Er rechnet damit, dass das Unternehmen bald einen positiven Cash-Flow aufweise!
Hier der LinK:
http://quote.bloomberg.com/fgcgi.cgi?s=AOiQf6hUTQ3VyaXMg&T=m…
Die Zulassung in Europa und Australien soll vorher erfolgen. Stryker wird OP-1 als NOVOS vermarkten und Curis zwischen 12 und 20% am Umsatz beteiligen! Ausserdem wird noch dieses Jahr der Beginn der nächsten Testphase für Vascugel bekannt gegeben!
Billiger geht`s fast nimmer. Doppelter Boden und Stützung bei 10$.
Also kaufen und abwarten und sich freuen...
@Westerheide aus dem Consors - Board, der hinsichtlich Curis immer am Ball ist. Ich stelle seinen Beitrag einfach mal ins Board und hoffe auf sein Einverständnis:
Auf der gestrigen Konferenz bei Robertson Stephens sagte Curis` CEO Platika, daß die Zulassung für OP-1 am Anfang nächsten Jahres erwartet wird (für Amerika!!!). Er schätze das jährliche Potential auf 1 Milliarde $. Ausserdem wird nächstes Jahr die Zulassung für Curis` 2. Produkt Chondrogel beantragt. Er rechnet damit, dass das Unternehmen bald einen positiven Cash-Flow aufweise!
Hier der LinK:
http://quote.bloomberg.com/fgcgi.cgi?s=AOiQf6hUTQ3VyaXMg&T=m…
Die Zulassung in Europa und Australien soll vorher erfolgen. Stryker wird OP-1 als NOVOS vermarkten und Curis zwischen 12 und 20% am Umsatz beteiligen! Ausserdem wird noch dieses Jahr der Beginn der nächsten Testphase für Vascugel bekannt gegeben!
Billiger geht`s fast nimmer. Doppelter Boden und Stützung bei 10$.
Also kaufen und abwarten und sich freuen...
News
Curis Names Daniel Passeri Senior Vice President of Corporate Development and Strategic Planning
CAMBRIDGE, Mass., Nov 29, 2000 (BW HealthWire) -- Curis, Inc. (NASDAQ: CRIS)
today announced the appointment of Daniel R. Passeri as senior vice president,
corporate development and strategic planing
Mr. Passeri comes to Curis from Gene Logic Inc, where he was senior vice
president, corporate development. At Gene Logic, he was responsible for
negotiating and overseeing alliance programs, managing the company`s
intellectual property portfolio and overall corporate development. Mr. Passeri
was previously director of technology management at Boehringer Mannheim, where
he established and coordinated business development projects through technology
acquisitions and corporate ventures. His prior positions at the National
Institutes of Health, New England Biolabs, Inc. and the U.S. Patent and
Trademark Office involved technology transfer, patent prosecution, and the
evaluation of commercial and marketing strategies.
"Dan Passeri`s extensive background in corporate development, licensing and
program management will serve Curis well as we shape and add depth to our broad
portfolio of technologies and product opportunities in regenerative medicine,"
said Doros Platika, M.D., president and chief executive officer of Curis. "In
addition, his experience in negotiating corporate alliances will help make
possible the timely development of certain programs that target large markets
and consequently will require the resources and commercialization infrastructure
of larger partners. Dan is a superb strategic thinker and implementer. He will
spearhead an aggressive corporate strategy to ensure that Curis is the premier
regenerative medicine company. "
Mr. Passeri earned a J.D. from the National Law Center at George Washington
University, with an emphasis on intellectual property, licensing, contract law,
negotiations and international business transactions. He holds an M.Sc. in
biotechnology from the University of London and is a cum laude graduate of
Northeastern University.
Curis, Inc. is developing products based on technologies in the emerging field
of regenerative medicine. The Company is combining insights gained through the
study of developmental biology with high-throughput screening capabilities,
proteins, cells and biocompatible materials to facilitate the development of new
regenerative medicine therapies. For more information, please visit the Curis
web site at http://www.curis.com.
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties including,
without limitation, risks associated with the inherent uncertainty of
pharmaceutical research, product development, regulatory approval and
commercialization, the impact of competitive products, patents, patent
litigation, product liability, third party reimbursement, and other risks and
uncertainties associated with the biotechnology industry. The completion of a
successful pre-clinical trial does not mean the Company will be able to
successfully commercialize the product. For additional factors that could cause
actual results to differ materially, please refer to the risk factors section of
the Curis joint proxy statement/prospectus filed with the Securities and
Exchange Commission on June 19, 2000 and Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on August 14, 2000.
gruß Steve de Ville auf steigende Kurse
Curis Names Daniel Passeri Senior Vice President of Corporate Development and Strategic Planning
CAMBRIDGE, Mass., Nov 29, 2000 (BW HealthWire) -- Curis, Inc. (NASDAQ: CRIS)
today announced the appointment of Daniel R. Passeri as senior vice president,
corporate development and strategic planing
Mr. Passeri comes to Curis from Gene Logic Inc, where he was senior vice
president, corporate development. At Gene Logic, he was responsible for
negotiating and overseeing alliance programs, managing the company`s
intellectual property portfolio and overall corporate development. Mr. Passeri
was previously director of technology management at Boehringer Mannheim, where
he established and coordinated business development projects through technology
acquisitions and corporate ventures. His prior positions at the National
Institutes of Health, New England Biolabs, Inc. and the U.S. Patent and
Trademark Office involved technology transfer, patent prosecution, and the
evaluation of commercial and marketing strategies.
"Dan Passeri`s extensive background in corporate development, licensing and
program management will serve Curis well as we shape and add depth to our broad
portfolio of technologies and product opportunities in regenerative medicine,"
said Doros Platika, M.D., president and chief executive officer of Curis. "In
addition, his experience in negotiating corporate alliances will help make
possible the timely development of certain programs that target large markets
and consequently will require the resources and commercialization infrastructure
of larger partners. Dan is a superb strategic thinker and implementer. He will
spearhead an aggressive corporate strategy to ensure that Curis is the premier
regenerative medicine company. "
Mr. Passeri earned a J.D. from the National Law Center at George Washington
University, with an emphasis on intellectual property, licensing, contract law,
negotiations and international business transactions. He holds an M.Sc. in
biotechnology from the University of London and is a cum laude graduate of
Northeastern University.
Curis, Inc. is developing products based on technologies in the emerging field
of regenerative medicine. The Company is combining insights gained through the
study of developmental biology with high-throughput screening capabilities,
proteins, cells and biocompatible materials to facilitate the development of new
regenerative medicine therapies. For more information, please visit the Curis
web site at http://www.curis.com.
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties including,
without limitation, risks associated with the inherent uncertainty of
pharmaceutical research, product development, regulatory approval and
commercialization, the impact of competitive products, patents, patent
litigation, product liability, third party reimbursement, and other risks and
uncertainties associated with the biotechnology industry. The completion of a
successful pre-clinical trial does not mean the Company will be able to
successfully commercialize the product. For additional factors that could cause
actual results to differ materially, please refer to the risk factors section of
the Curis joint proxy statement/prospectus filed with the Securities and
Exchange Commission on June 19, 2000 and Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on August 14, 2000.
gruß Steve de Ville
auf steigende Kurse
moin moin
unsere geduld wierd
sich auszahlen
mfg
unsere geduld wierd
sich auszahlen
mfg
Curis positioniert sich mit einem neuen Mann, der über umgangreiche Erfahrungen und Kontakte verfügt. Nachfolgend eine (Altavista) - Übersetzung des zuvor schon Steve reingestellten Postings:
Curis benennt Daniel Passeri Vizepräsidenten der mit Zuständigkeit der Entwicklung und der strategischen Planung Cambridge, Mass. -- (BW HealthWire) -- Nov.. 29, 2000 -- Curis, Inc. (Nasdaq: CRIS) verkündete heute die Verpflichtungng von Daniel R. Passeri als Senior – Vizepräsident mit Zuständigkeit für korporative Entwicklung und strategische Planung. Herr Passeri kommt zu Curis von der Genlogik Inc., in der er Senior Vizepräsident An der Genlogik war er für das Marketing und das Beaufsichtigen von Kooperationen verantwortlich und Herr Passeri war vorher Direktor des Technologiemanagements bei Boehringer Mannheim, in dem er geschäftliche Entwicklung Projekte durch Technologiedatenerfassungen und Unternehmensneugründungen herstellte und koordinierte. Seine vorherigen Positionen an dem National Health Institit, von New.england, Biolabs, Inc. und beim US-Patentamt geben Passeri die Erfahrung im Bereich Entwicklung, Genehmigung und Programmmanagement , um Produktgelegenheiten in der verbessernden Medizin zu formen und hinzufügen, " sagte Doros Platika, M.D., Präsident und Generaldirektor von Curis. " zusätzlich, hilft seine Erfahrung, wenn sie über korporative Bündnisse verhandelt, die fristgerechte Entwicklung von bestimmten Programmen zu ermöglichen, die große Märkte zielen und infolgedessen benötigt die Betriebsmittel und die Kommerzialisierunginfrastruktur der größeren Partner. Dan ist ein großartiger strategischer Denker und ein Implementer. Er Willensspearhead eine konkurrenzfähige korporative Strategie zum Sicherstellen, daß Curis der Premier Herr Passeri der verbessernden Medizinfirma " ist, erwarb ein J.D. von der Mitte des staatlichen Rechts an der Universität George Washington, mit einem Hauptgewicht auf geistigem Eigentum, dem Genehmigen, Vertrag Gesetz, Vermittlungen und internationalen Geschäften. Er hält ein M.Sc. in der Biotechnologie von der Universität von London an und ist a mit laudeabsolvent der nordöstlichen Universität. Curis, Inc. entwickelt die Produkte, die auf Technologien auf dem auftauchenden Gebiet der verbessernden Medizin basieren. Die Firma kombiniert die Einblicke, die durch die Studie der Entwicklungsbiologie mit Hochdurchsatzsiebungfähigkeiten, Proteinen, Zellen und biocompatible Materialien gewonnen werden, um die Entwicklung der neuen verbessernden Medizintherapien zu erleichtern. Zu mehr Information besuchen Sie bitte die Web site Curis an http://www.curis.com. Die Anweisungen in diesen Nachrichten geben frei, die nicht historische Tatsachen Vorwärts-forward-looking Anweisungen sind, deren Gefahren und Ungewißheiten einschließlich, ohne Beschränkung, die Gefahren miteinbeziehen Sie, die mit der zugehörigen Ungewißheit der pharmazeutischen Forschung dazugehörig sind, Produktentwicklung, Genehmigung durch die zuständige Aufsichtsbehörde und Kommerzialisierung, die Auswirkung der konkurrierenden Produkte, Patente, Patentrechtsstreit, Zuverläßlichkeit von Produkten, Vergütung des dritten Beteiligten und andere Gefahren und Ungewißheiten, die mit der Biotechnologieindustrie dazugehörig sind. Die Beendigung eines erfolgreichen vor-klinischen Versuches bedeutet nicht, daß die Firma kann, das Produkt erfolgreich in den Handel zu bringen. Für zusätzliche Faktoren, die tatsächliche Resultate veranlassen konnten, um sich materiell zu unterscheiden, das Gefahr Faktorkapitel des gemeinsamen Proxy statement/prospectus bitte anzusprechen Curis archiviert mit den Aktien und der Austauschkommission an Juni 19, 2000 und vierteljährlicher Report auf Formular 10-Q archiviert mit den Aktien und der Austauschkommission an August 14, 2000. KONTAKT: Curis, Inc.. William B. Boni (617) 503-6506 oder Cynthia Clayton (617) 503-6641
Curis benennt Daniel Passeri Vizepräsidenten der mit Zuständigkeit der Entwicklung und der strategischen Planung Cambridge, Mass. -- (BW HealthWire) -- Nov.. 29, 2000 -- Curis, Inc. (Nasdaq: CRIS) verkündete heute die Verpflichtungng von Daniel R. Passeri als Senior – Vizepräsident mit Zuständigkeit für korporative Entwicklung und strategische Planung. Herr Passeri kommt zu Curis von der Genlogik Inc., in der er Senior Vizepräsident An der Genlogik war er für das Marketing und das Beaufsichtigen von Kooperationen verantwortlich und Herr Passeri war vorher Direktor des Technologiemanagements bei Boehringer Mannheim, in dem er geschäftliche Entwicklung Projekte durch Technologiedatenerfassungen und Unternehmensneugründungen herstellte und koordinierte. Seine vorherigen Positionen an dem National Health Institit, von New.england, Biolabs, Inc. und beim US-Patentamt geben Passeri die Erfahrung im Bereich Entwicklung, Genehmigung und Programmmanagement , um Produktgelegenheiten in der verbessernden Medizin zu formen und hinzufügen, " sagte Doros Platika, M.D., Präsident und Generaldirektor von Curis. " zusätzlich, hilft seine Erfahrung, wenn sie über korporative Bündnisse verhandelt, die fristgerechte Entwicklung von bestimmten Programmen zu ermöglichen, die große Märkte zielen und infolgedessen benötigt die Betriebsmittel und die Kommerzialisierunginfrastruktur der größeren Partner. Dan ist ein großartiger strategischer Denker und ein Implementer. Er Willensspearhead eine konkurrenzfähige korporative Strategie zum Sicherstellen, daß Curis der Premier Herr Passeri der verbessernden Medizinfirma " ist, erwarb ein J.D. von der Mitte des staatlichen Rechts an der Universität George Washington, mit einem Hauptgewicht auf geistigem Eigentum, dem Genehmigen, Vertrag Gesetz, Vermittlungen und internationalen Geschäften. Er hält ein M.Sc. in der Biotechnologie von der Universität von London an und ist a mit laudeabsolvent der nordöstlichen Universität. Curis, Inc. entwickelt die Produkte, die auf Technologien auf dem auftauchenden Gebiet der verbessernden Medizin basieren. Die Firma kombiniert die Einblicke, die durch die Studie der Entwicklungsbiologie mit Hochdurchsatzsiebungfähigkeiten, Proteinen, Zellen und biocompatible Materialien gewonnen werden, um die Entwicklung der neuen verbessernden Medizintherapien zu erleichtern. Zu mehr Information besuchen Sie bitte die Web site Curis an http://www.curis.com. Die Anweisungen in diesen Nachrichten geben frei, die nicht historische Tatsachen Vorwärts-forward-looking Anweisungen sind, deren Gefahren und Ungewißheiten einschließlich, ohne Beschränkung, die Gefahren miteinbeziehen Sie, die mit der zugehörigen Ungewißheit der pharmazeutischen Forschung dazugehörig sind, Produktentwicklung, Genehmigung durch die zuständige Aufsichtsbehörde und Kommerzialisierung, die Auswirkung der konkurrierenden Produkte, Patente, Patentrechtsstreit, Zuverläßlichkeit von Produkten, Vergütung des dritten Beteiligten und andere Gefahren und Ungewißheiten, die mit der Biotechnologieindustrie dazugehörig sind. Die Beendigung eines erfolgreichen vor-klinischen Versuches bedeutet nicht, daß die Firma kann, das Produkt erfolgreich in den Handel zu bringen. Für zusätzliche Faktoren, die tatsächliche Resultate veranlassen konnten, um sich materiell zu unterscheiden, das Gefahr Faktorkapitel des gemeinsamen Proxy statement/prospectus bitte anzusprechen Curis archiviert mit den Aktien und der Austauschkommission an Juni 19, 2000 und vierteljährlicher Report auf Formular 10-Q archiviert mit den Aktien und der Austauschkommission an August 14, 2000. KONTAKT: Curis, Inc.. William B. Boni (617) 503-6506 oder Cynthia Clayton (617) 503-6641
Curis News
Curis Names Andrew Uprichard COO
CAMBRIDGE, Mass., Nov 30, 2000 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS)
today announced the appointment of Andrew C. G. Uprichard as chief operating
officer.
Dr. Uprichard joins Curis from Pfizer Global Research and Development, where he
was most recently vice president, drug development. He held a number of
positions at the Parke-Davis division of Warner Lambert Company during an
eleven-year period prior to its merger earlier this year with Pfizer, including
senior director of the cardiovascular clinical group and senior director of the
cardiovascular discovery effort.
Dr. Uprichard was responsible for the complete range of compound development
activities for the cardiovascular and anti-infective portfolios at Parke-Davis,
from early pre-clinical development through commercialization. He helped set
strategic priorities for drug development in these therapeutic areas and managed
all related line functions, including chemical development, formulation,
clinical pharmacology, clinical development, regulatory affairs, marketing,
legal, supply chain and manufacturing.
"Andrew Uprichard brings to Curis a dynamic and market-oriented approach to
therapeutic product development," said Doros Platika, M.D., president and chief
executive officer of Curis. "His extensive experience at a pharmaceutical
industry leader encompasses virtually every important function required for
successful drug development. Andrew is an outstanding addition to the Curis
management team and arrives at a particularly opportune time."
A medical graduate of the University of Edinburgh, Scotland, Dr. Uprichard
completed his residency training in the United Kingdom before taking positions
as a cardiology fellow and postdoctoral research fellow at the University of
Michigan Medical School. He is a fellow of the Royal College of Physicians in
the United Kingdom and a fellow of the American College of Physicians.
Curis, Inc. is developing products based on technologies in the emerging field
of regenerative medicine. The Company is combining insights gained through the
study of developmental biology with high-throughput screening capabilities,
proteins, cells and biocompatible materials to facilitate the development of new
regenerative medicine therapies. For more information, please visit the Curis
web site at http://www.curis.com.
gruß Steve de Ville auf steigende Kurse
Curis Names Andrew Uprichard COO
CAMBRIDGE, Mass., Nov 30, 2000 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS)
today announced the appointment of Andrew C. G. Uprichard as chief operating
officer.
Dr. Uprichard joins Curis from Pfizer Global Research and Development, where he
was most recently vice president, drug development. He held a number of
positions at the Parke-Davis division of Warner Lambert Company during an
eleven-year period prior to its merger earlier this year with Pfizer, including
senior director of the cardiovascular clinical group and senior director of the
cardiovascular discovery effort.
Dr. Uprichard was responsible for the complete range of compound development
activities for the cardiovascular and anti-infective portfolios at Parke-Davis,
from early pre-clinical development through commercialization. He helped set
strategic priorities for drug development in these therapeutic areas and managed
all related line functions, including chemical development, formulation,
clinical pharmacology, clinical development, regulatory affairs, marketing,
legal, supply chain and manufacturing.
"Andrew Uprichard brings to Curis a dynamic and market-oriented approach to
therapeutic product development," said Doros Platika, M.D., president and chief
executive officer of Curis. "His extensive experience at a pharmaceutical
industry leader encompasses virtually every important function required for
successful drug development. Andrew is an outstanding addition to the Curis
management team and arrives at a particularly opportune time."
A medical graduate of the University of Edinburgh, Scotland, Dr. Uprichard
completed his residency training in the United Kingdom before taking positions
as a cardiology fellow and postdoctoral research fellow at the University of
Michigan Medical School. He is a fellow of the Royal College of Physicians in
the United Kingdom and a fellow of the American College of Physicians.
Curis, Inc. is developing products based on technologies in the emerging field
of regenerative medicine. The Company is combining insights gained through the
study of developmental biology with high-throughput screening capabilities,
proteins, cells and biocompatible materials to facilitate the development of new
regenerative medicine therapies. For more information, please visit the Curis
web site at http://www.curis.com.
gruß Steve de Ville
auf steigende Kurse
Hi ihr!
Ist euch schon mal aufgefallen, dass Curis jetzt schon den zweíten Mann geholt hat der Ahnung von Vermarktung und Zulassung hat?
Hört sich doch echt gut an oder? Das könnte in der nächsten Zeit unsere heiß erwarteten News bringen (Zulassung).
Wolln wir mal hoffen
Auf einen hübschen Anstieg
Pteppic
Ist euch schon mal aufgefallen, dass Curis jetzt schon den zweíten Mann geholt hat der Ahnung von Vermarktung und Zulassung hat?
Hört sich doch echt gut an oder? Das könnte in der nächsten Zeit unsere heiß erwarteten News bringen (Zulassung).
Wolln wir mal hoffen
Auf einen hübschen Anstieg
Pteppic
CURIS GO
News about CURIS -CREATIVE BIOMOLECULAS Mexican Authorities, Tequila Makers Talk Tax Cuts
WEDNESDAY, DECEMBER 06, 2000 4:52 PM
- Infolatina S.A. De C.V.
MEXICO CITY, Dec 6, 2000 (El Universal/Infolatina via COMTEX) -- Mexican tequila makers have asked the government to lower the rate of tax levied on the popular beverage. National Tequila Industry Council leader Alberto Curis Garcia on Tuesday said industry representatives met with Finance Ministry senior official Ruben Aguirre to request that the rate of special products and services tax (IEPS) levied on tequila be reduced from 54 percent to 50 percent. Curis said tequila makers pay 40 percent more tax than producers of comparable beverages in the United States and Canada. He said the domestic price of tequila has risen 30 percent during the past 18 months, and urged the Finance ministry to take into account that the industry provides employment for 35,500 Mexicans in rural areas. "Tequila is an important Mexican national emblem abroad," he said. In 1999, 190 million liters of tequila were sold, said Curis, predicting that the figure for the current year will be down by 5 percent.
Astimates:STRONG BUY
Copyright 2000 Infolatina, all rights reserved.
SUBJECT
KANN JEMAND ÜBERSETZEN???
WEDNESDAY, DECEMBER 06, 2000 4:52 PM
- Infolatina S.A. De C.V.
MEXICO CITY, Dec 6, 2000 (El Universal/Infolatina via COMTEX) -- Mexican tequila makers have asked the government to lower the rate of tax levied on the popular beverage. National Tequila Industry Council leader Alberto Curis Garcia on Tuesday said industry representatives met with Finance Ministry senior official Ruben Aguirre to request that the rate of special products and services tax (IEPS) levied on tequila be reduced from 54 percent to 50 percent. Curis said tequila makers pay 40 percent more tax than producers of comparable beverages in the United States and Canada. He said the domestic price of tequila has risen 30 percent during the past 18 months, and urged the Finance ministry to take into account that the industry provides employment for 35,500 Mexicans in rural areas. "Tequila is an important Mexican national emblem abroad," he said. In 1999, 190 million liters of tequila were sold, said Curis, predicting that the figure for the current year will be down by 5 percent.
Astimates:STRONG BUY
Copyright 2000 Infolatina, all rights reserved.
SUBJECT
KANN JEMAND ÜBERSETZEN???
@mandic
Der Text ist nicht dein ernst ??
Wenn es Witz sein soll ist er gut, ist doch ein Witz oder ???
Was soll das Strong Buy unter dem Text ??
Soll ich den Vorsitzenden der Tequilaindustrie Herr Curis kaufen ???
macht es jut Kinings
Der Text ist nicht dein ernst ??
Wenn es Witz sein soll ist er gut, ist doch ein Witz oder ???
Was soll das Strong Buy unter dem Text ??
Soll ich den Vorsitzenden der Tequilaindustrie Herr Curis kaufen ???
macht es jut Kinings
Hi Leute
da hat mandic was verwechselt
kam zwar zu Curis News aber die Meldung
bezog sich auf einen Alberto Curis Garcia
also leider kein strong bye für Curis
ansonsten nehm ich jetzt mir einen Tequilla
bei so scheiß Kursen
hmmmmm weiß oder braun
am besten beide
gruß Steve de Ville auf steigende Kurse
da hat mandic was verwechselt
kam zwar zu Curis News aber die Meldung
bezog sich auf einen Alberto Curis Garcia
also leider kein strong bye für Curis
ansonsten nehm ich jetzt mir einen Tequilla
bei so scheiß Kursen
hmmmmm weiß oder braun
am besten beide
gruß Steve de Ville
auf steigende Kurse 
Strong buy für Tequila.
Ich bevorzuge allerdings Gin oder Whisky, wenn`s denn was Härteres sein muß.
moin moin
was meint ihr
ab wan kann icn die sauferei einstellen?????
mfg
was meint ihr
ab wan kann icn die sauferei einstellen?????
mfg
Ich warte immer noch auf Nachricht bzgl. OP-1. Jetzt muß es doch langsam soweit sein. Ansonsten: Cheers!
Im Consors - Board wird verbreitet, dass Stryker Corp. heute die Zulassung von OP 1 in Ausralien verkündet hat.
Nächste Zulassung soll in Europa erfolgen. Ich bin gespannt, mit welcher Begründung die FED daan eine Zulassung in den USA verhindern will.
Nächste Zulassung soll in Europa erfolgen. Ich bin gespannt, mit welcher Begründung die FED daan eine Zulassung in den USA verhindern will.
Hi ,Captain
Stimmt,ist aber auch nur ne Empfehlung zur Zulassung
Ähnlich wie in Europa.
Stimmt,ist aber auch nur ne Empfehlung zur Zulassung
Ähnlich wie in Europa.
Zumindest ist die Nachricht besser, als wenn einem im Dunkeln jemand mit einem Messer nachläuft.
Ich überlege, CRIS langsam wieder zurückzukaufen, da sich der Kurs zwischen 6 und 7 $ offenbar stabilisiert hat.
Friday February 16, 1:18 pm Eastern Time
Press Release
Australian Agency Recommends Approval of First Biotech Product for Orthopaedic Medicine
Curis Comments On Report From Licensee
CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 16, 2001--Curis, Inc. (NASDAQ:CRIS - news) today commented on an announcement from Stryker Corporation (NYSE:SYK - news) regarding the positive opinion of the Australian Drug Evaluation Committee (ADEC) to recommend the granting of marketing authorization for OP-1 Implant (Osteogenic Protein 1) in Australia. OP-1, under license by Curis to Stryker Corporation for orthopaedic and periodontal indications in exchange for royalty payments as a percentage of sales, is the first biotechnology product recommended for use specifically in the field of orthopaedic medicine.
``We are delighted that OP-1, Curis` lead product, has now been recommended for regulatory agency approval in two geographic jurisdictions, Australia and Europe,`` said Doros Platika, M.D., president and chief executive officer of Curis.
``As one of the first regenerative medicine products recommended for approval in the world, OP-1 validates the rich product pipeline under development at Curis,`` said Dr. Platika. ``OP-1 is the most advanced product based on the developmental biology technology of Curis. Morphogenic proteins such as OP-1 have been shown to play a key role in a wide variety of tissues, and our research encompasses a number of indications involving tissue regeneration. OP-1 represents potential near-term revenue for Curis that will fuel this research and related clinical development.``
The product recommended for marketing authorization is a combination of the OP-1 protein and a collagen carrier in a wetted paste, which is surgically implanted into the bone defect. The indication recommended by ADEC is the treatment of nonunion of long bone fractures secondary to trauma for the purposes of initiating repair by new bone formation.
The ADEC opinion will now be considered by the Therapeutic Goods Agency, which is expected to make the final decision regarding marketing authorization in two to three months. OP-1 is also under review by regulatory agencies in the U.S. and Europe, where the Committee for Proprietary Medicinal Products (CPMP) recently issued a unanimous positive recommendation of marketing authorization for the product.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
Ich überlege, CRIS langsam wieder zurückzukaufen, da sich der Kurs zwischen 6 und 7 $ offenbar stabilisiert hat.
Friday February 16, 1:18 pm Eastern Time
Press Release
Australian Agency Recommends Approval of First Biotech Product for Orthopaedic Medicine
Curis Comments On Report From Licensee
CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 16, 2001--Curis, Inc. (NASDAQ:CRIS - news) today commented on an announcement from Stryker Corporation (NYSE:SYK - news) regarding the positive opinion of the Australian Drug Evaluation Committee (ADEC) to recommend the granting of marketing authorization for OP-1 Implant (Osteogenic Protein 1) in Australia. OP-1, under license by Curis to Stryker Corporation for orthopaedic and periodontal indications in exchange for royalty payments as a percentage of sales, is the first biotechnology product recommended for use specifically in the field of orthopaedic medicine.
``We are delighted that OP-1, Curis` lead product, has now been recommended for regulatory agency approval in two geographic jurisdictions, Australia and Europe,`` said Doros Platika, M.D., president and chief executive officer of Curis.
``As one of the first regenerative medicine products recommended for approval in the world, OP-1 validates the rich product pipeline under development at Curis,`` said Dr. Platika. ``OP-1 is the most advanced product based on the developmental biology technology of Curis. Morphogenic proteins such as OP-1 have been shown to play a key role in a wide variety of tissues, and our research encompasses a number of indications involving tissue regeneration. OP-1 represents potential near-term revenue for Curis that will fuel this research and related clinical development.``
The product recommended for marketing authorization is a combination of the OP-1 protein and a collagen carrier in a wetted paste, which is surgically implanted into the bone defect. The indication recommended by ADEC is the treatment of nonunion of long bone fractures secondary to trauma for the purposes of initiating repair by new bone formation.
The ADEC opinion will now be considered by the Therapeutic Goods Agency, which is expected to make the final decision regarding marketing authorization in two to three months. OP-1 is also under review by regulatory agencies in the U.S. and Europe, where the Committee for Proprietary Medicinal Products (CPMP) recently issued a unanimous positive recommendation of marketing authorization for the product.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
Robertsen Stephens:
Kauf Rating für Syk.
Begründung:Erwartungen der Zulassungen für OP-1 in EU u. Aus.
Datum : 20.02.2001
unter anderem :
Strong by für ophm:
Begründung:FDA OK für Arestin.
Kauf Rating für Syk.
Begründung:Erwartungen der Zulassungen für OP-1 in EU u. Aus.
Datum : 20.02.2001
unter anderem :
Strong by für ophm:
Begründung:FDA OK für Arestin.
Curis Reports Fourth Quarter and Fiscal 2000 Results
CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 23, 2001--Curis, Inc. (NASDAQ:CRIS - news) today reported the results of its operations for the three- and twelve-month periods ended December 31, 2000. These results include combined results of the three companies merged into Curis as described below. Due to the completion of merger in the middle of 2000 and the associated non-cash charges, the historical financial information and the comparison to prior years is provided but does not accurately reflect the change in Curis` business operations.
Excluding one-time costs and expenses, amortization of intangibles and stock-based compensation, total net loss for the three months ended December 31, 2000 was $9,233,000, or $0.34 per share. Financial results for the three-month period ended December 31, 2000 included two significant, non-cash expenses associated with the formation of Curis and the merger occurring on July 31, 2000 which are as follows: stock-based compensation of $4,133,000 and amortization of intangible assets of $5,803,000.
Curis` cash and investment balance on December 31, 2000 was $75,799,000. Curis had 31,383,585 shares outstanding on December 31, 2000.
``Curis has successfully completed its first fiscal year. It was a year that saw the successful consummation of a merger among three companies and the creation of a robust portfolio of technologies and products. Recently Curis increased its cash reserve and expanded its stem cell portfolio. Curis is poised to become the premier regenerative medicine company,`` said Doros Platika, M.D., president and chief executive officer of Curis.
``During the final quarter of the year, we expanded our core management team with the addition of Dr. Andrew Uprichard as chief operating officer and Daniel Passeri as senior vice president, corporate development and strategic planning,`` said Dr. Platika. ``These individuals, who bring extensive experience in clinical development and negotiating corporate alliances, respectively, reflect dual priorities at Curis for 2001.
``Early in 2001, regulatory activities related to the Company`s lead product, OP-1 for non-union bone fractures, included a unanimous recommendation for approval by European authorities and a recommendation for approval by the Australian authorities,`` said Dr. Platika. ``In addition, our OP-1 marketing partner, Stryker Corporation, received a Not-Approvable letter from the U.S. FDA. We will report on developments in all three jurisdictions as they unfold in the coming months. In the meantime, Stryker is continuing its clinical trials with OP-1 in fresh fractures and spinal fusion.
``On the licensing front, Curis entered into an agreement with Aegera Therapeutics Inc. granting Curis an exclusive worldwide license of Aegera`s skin-derived, adult stem cell technologies and establishing a broad collaboration to investigate the therapeutic potential of these technologies in neurological, pancreatic and cardiovascular disorders,`` said Dr. Platika. ``Aegera`s work in stem cell biology suggests that stem cells present in adult skin, an easily accessible source of pluripotent stem cells, may give rise to a variety of cell types that go beyond their tissue of origin. Curis` expertise with stem cells, growth factors and small molecules, combined with Aegera`s technology, represents a dynamic paradigm for developing innovative regenerative medicine therapeutics.
``Finally, research published in Nature Immunology (February 2001), demonstrated for the first time the role of two protein families in the expansion of human blood stem cells that retain the capacity to differentiate into any one of the body`s different blood cells,`` said Dr. Platika. ``The two protein families identified in this study interact to control one of the critical functions of the human body known as hematopoiesis, or the formation of the blood and immune system. Both families are central elements in the Curis intellectual property and technology portfolio. Curis is uniquely positioned, therefore, to develop and commercialize products based on discoveries related to these proteins.``
Primarily as a result of non-cash charges totaling $325,879,000 associated with the merger, Curis reported a net loss of $350,351,000 or $19.80 per share, for the year ended December 31, 2000, compared with Creative BioMolecules, Inc., the predecessor company of Curis, which had a net loss of $14,505,000, or $1.36 per share, for the year ended December 31, 1999. Financial results for the year ended December 31, 2000 included a number of significant, non-cash charges and other merger-related cash expenses associated with the merger. These include costs and expenses as follows: a one-time non-cash charge of $294,800,000 resulting from the allocated portion of the purchase price of Ontogeny and Reprogenesis identified under the accounting rules as in-process research and development; stock-based compensation of $16,628,000; amortization of intangible assets of $14,451,000; severance paid to former executive officers and former employees of $1,955,000; and a loss on the disposition of assets of $204,000.
Total revenues for the year ended December 31, 2000 were $1,024,000 as compared to $3,212,000 for the same period in 1999. The decrease in revenues was primarily the result of the termination of a research agreement with Biogen, Inc. in 1999, which was partially offset by revenues earned under a National Institute of Standards and Technology (NIST) grant received in November 1999.
Total operating expenses, when excluding one-time costs and expenses, amortization of intangibles and stock-based compensation, for the year ended December 31, 2000 were $26,754,000, as compared to $15,959,000 for the same period in 1999.
For the year ended December 31, 2000, total other income was $1,425,000, as compared to $1,765,000 for the same period in 1999. The decrease was due to a lower average available investment balance as compared to the prior year and a higher average balance of lease obligations from the consolidation of the merger.
``In December, Curis closed a private placement offering that raised $46.8 million in gross proceeds from the sale of newly issued shares placed with a group of institutional investors,`` said George A. Eldridge, vice president, finance, and chief financial officer. ``This transaction, completed on a timely basis during a period of volatility in the financial markets, significantly increased the financial resources of the company.
``It is important to note that the loss for Fiscal 2000 of $350,351,000 was primarily the result of non-cash items due to accounting requirements associated with the merger and even included a one-time non-cash charge of over $294,800,000 related to in-process research and development acquired during the merger,`` said Mr. Eldridge. ``Going forward, we are projecting our gross operating expenditures to approximate $10 million per quarter which, with our capital resources totaling $75,799,000 as of December 31, 2000, gives us sufficient resources to operate for almost two years.``
On July 31, 2000, Creative BioMolecules, Inc. (formerly NASDAQ: CBMI), Ontogeny, Inc., and Reprogenesis, Inc., merged with and into Curis, Inc. On that date, Curis, as the surviving company of the merger, assumed the rights and obligations of Creative, Ontogeny and Reprogenesis. Immediately after the merger, Curis was owned approximately 43 percent by the former stockholders of Creative, 38 percent by the former stockholders of Ontogeny and 19 percent by the former stockholders of Reprogenesis. Consequently, for accounting purposes, Curis is deemed to be the successor to Creative, and the historical financial statements of Creative have become the historical financial statements of Curis.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis Registration Statement filed on Form S-1 with the Securities and Exchange Commission on December 19, 2000 and Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on December 6, 2000.
CURIS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three months ended Year ended
December 31, December 31,
2000 1999 2000 1999
Revenues $279,756 $806,100 $1,023,569 $3,211,860
Operating expenses:
Research and
development 7,351,433 2,362,218 17,423,895 10,434,560
General and
administrative 2,687,443 1,445,890 9,330,256 5,524,077
Stock-based
compensation 4,132,628 -- 16,628,216 64,000
Amortization of
intangible
assets 5,803,422 482,312 14,450,896 808,017
Gain (loss) on
disposition of
fixed assets (44,612) -- 203,904 --
In-process research
& development -- -- 294,800,000 --
1999 reorganization
and 1998 sale of
manufacturing
operations -- 255,701 (38,391) 255,701
Total operating
expenses 19,930,314 4,546,121 352,798,776 17,086,355
Net loss from
operations (19,650,558) (3,740,021) (351,775,207) (13,874,495)
Interest and
other income 741,641 308,513 1,905,893 1,926,090
Interest expense (215,948) (46,605) (481,310) (161,385)
Total other
income 525,693 261,908 1,424,583 1,764,705
Net loss $(19,124,865) $(3,478,113) $(350,350,624) $(12,109,790)
Accretion and
repurchase costs
on Series 1998/A
Preferred Stock -- -- -- (2,395,559)
Net loss
applicable
to common
stockholders $(19,124,865) $(3,478,113) $(350,350,624) $(14,505,349)
Basic and
diluted
net loss per
common share $(0.71) $(0.32) $(19.80) $(1.36)
Weighted average
common shares
for basic and
diluted net loss
computation 26,786,175 10,868,052 17,693,996 10,681,547
CURIS, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
December 31, December 31,
2000 1999
ASSETS
Cash, cash equivalents and
marketable securities $ 75,798,610 $ 21,370,585
Property and equipment, net 7,866,591 2,130,158
Intangible assets 97,145,664 5,075,914
Other assets 1,871,125 315,634
Total assets $182,681,990 $ 28,892,291
LIABILITIES AND STOCKHOLDERS` EQUITY
Accounts payable and accrued expenses $ 7,741,465 $ 4,113,994
Debt and capital lease obligations 6,126,759 1,356,711
Total liabilities 13,868,224 5,470,705
Total stockholders` equity 168,813,766 23,421,586
Total liabilities and
stockholders` equity $182,681,990 $ 28,892,291
--------------------------------------------------------------------------------
Contact:
Curis, Inc.
George Eldridge
(617) 503-6515
or
Cynthia Clayton
(617) 503-6641
CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 23, 2001--Curis, Inc. (NASDAQ:CRIS - news) today reported the results of its operations for the three- and twelve-month periods ended December 31, 2000. These results include combined results of the three companies merged into Curis as described below. Due to the completion of merger in the middle of 2000 and the associated non-cash charges, the historical financial information and the comparison to prior years is provided but does not accurately reflect the change in Curis` business operations.
Excluding one-time costs and expenses, amortization of intangibles and stock-based compensation, total net loss for the three months ended December 31, 2000 was $9,233,000, or $0.34 per share. Financial results for the three-month period ended December 31, 2000 included two significant, non-cash expenses associated with the formation of Curis and the merger occurring on July 31, 2000 which are as follows: stock-based compensation of $4,133,000 and amortization of intangible assets of $5,803,000.
Curis` cash and investment balance on December 31, 2000 was $75,799,000. Curis had 31,383,585 shares outstanding on December 31, 2000.
``Curis has successfully completed its first fiscal year. It was a year that saw the successful consummation of a merger among three companies and the creation of a robust portfolio of technologies and products. Recently Curis increased its cash reserve and expanded its stem cell portfolio. Curis is poised to become the premier regenerative medicine company,`` said Doros Platika, M.D., president and chief executive officer of Curis.
``During the final quarter of the year, we expanded our core management team with the addition of Dr. Andrew Uprichard as chief operating officer and Daniel Passeri as senior vice president, corporate development and strategic planning,`` said Dr. Platika. ``These individuals, who bring extensive experience in clinical development and negotiating corporate alliances, respectively, reflect dual priorities at Curis for 2001.
``Early in 2001, regulatory activities related to the Company`s lead product, OP-1 for non-union bone fractures, included a unanimous recommendation for approval by European authorities and a recommendation for approval by the Australian authorities,`` said Dr. Platika. ``In addition, our OP-1 marketing partner, Stryker Corporation, received a Not-Approvable letter from the U.S. FDA. We will report on developments in all three jurisdictions as they unfold in the coming months. In the meantime, Stryker is continuing its clinical trials with OP-1 in fresh fractures and spinal fusion.
``On the licensing front, Curis entered into an agreement with Aegera Therapeutics Inc. granting Curis an exclusive worldwide license of Aegera`s skin-derived, adult stem cell technologies and establishing a broad collaboration to investigate the therapeutic potential of these technologies in neurological, pancreatic and cardiovascular disorders,`` said Dr. Platika. ``Aegera`s work in stem cell biology suggests that stem cells present in adult skin, an easily accessible source of pluripotent stem cells, may give rise to a variety of cell types that go beyond their tissue of origin. Curis` expertise with stem cells, growth factors and small molecules, combined with Aegera`s technology, represents a dynamic paradigm for developing innovative regenerative medicine therapeutics.
``Finally, research published in Nature Immunology (February 2001), demonstrated for the first time the role of two protein families in the expansion of human blood stem cells that retain the capacity to differentiate into any one of the body`s different blood cells,`` said Dr. Platika. ``The two protein families identified in this study interact to control one of the critical functions of the human body known as hematopoiesis, or the formation of the blood and immune system. Both families are central elements in the Curis intellectual property and technology portfolio. Curis is uniquely positioned, therefore, to develop and commercialize products based on discoveries related to these proteins.``
Primarily as a result of non-cash charges totaling $325,879,000 associated with the merger, Curis reported a net loss of $350,351,000 or $19.80 per share, for the year ended December 31, 2000, compared with Creative BioMolecules, Inc., the predecessor company of Curis, which had a net loss of $14,505,000, or $1.36 per share, for the year ended December 31, 1999. Financial results for the year ended December 31, 2000 included a number of significant, non-cash charges and other merger-related cash expenses associated with the merger. These include costs and expenses as follows: a one-time non-cash charge of $294,800,000 resulting from the allocated portion of the purchase price of Ontogeny and Reprogenesis identified under the accounting rules as in-process research and development; stock-based compensation of $16,628,000; amortization of intangible assets of $14,451,000; severance paid to former executive officers and former employees of $1,955,000; and a loss on the disposition of assets of $204,000.
Total revenues for the year ended December 31, 2000 were $1,024,000 as compared to $3,212,000 for the same period in 1999. The decrease in revenues was primarily the result of the termination of a research agreement with Biogen, Inc. in 1999, which was partially offset by revenues earned under a National Institute of Standards and Technology (NIST) grant received in November 1999.
Total operating expenses, when excluding one-time costs and expenses, amortization of intangibles and stock-based compensation, for the year ended December 31, 2000 were $26,754,000, as compared to $15,959,000 for the same period in 1999.
For the year ended December 31, 2000, total other income was $1,425,000, as compared to $1,765,000 for the same period in 1999. The decrease was due to a lower average available investment balance as compared to the prior year and a higher average balance of lease obligations from the consolidation of the merger.
``In December, Curis closed a private placement offering that raised $46.8 million in gross proceeds from the sale of newly issued shares placed with a group of institutional investors,`` said George A. Eldridge, vice president, finance, and chief financial officer. ``This transaction, completed on a timely basis during a period of volatility in the financial markets, significantly increased the financial resources of the company.
``It is important to note that the loss for Fiscal 2000 of $350,351,000 was primarily the result of non-cash items due to accounting requirements associated with the merger and even included a one-time non-cash charge of over $294,800,000 related to in-process research and development acquired during the merger,`` said Mr. Eldridge. ``Going forward, we are projecting our gross operating expenditures to approximate $10 million per quarter which, with our capital resources totaling $75,799,000 as of December 31, 2000, gives us sufficient resources to operate for almost two years.``
On July 31, 2000, Creative BioMolecules, Inc. (formerly NASDAQ: CBMI), Ontogeny, Inc., and Reprogenesis, Inc., merged with and into Curis, Inc. On that date, Curis, as the surviving company of the merger, assumed the rights and obligations of Creative, Ontogeny and Reprogenesis. Immediately after the merger, Curis was owned approximately 43 percent by the former stockholders of Creative, 38 percent by the former stockholders of Ontogeny and 19 percent by the former stockholders of Reprogenesis. Consequently, for accounting purposes, Curis is deemed to be the successor to Creative, and the historical financial statements of Creative have become the historical financial statements of Curis.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis Registration Statement filed on Form S-1 with the Securities and Exchange Commission on December 19, 2000 and Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on December 6, 2000.
CURIS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three months ended Year ended
December 31, December 31,
2000 1999 2000 1999
Revenues $279,756 $806,100 $1,023,569 $3,211,860
Operating expenses:
Research and
development 7,351,433 2,362,218 17,423,895 10,434,560
General and
administrative 2,687,443 1,445,890 9,330,256 5,524,077
Stock-based
compensation 4,132,628 -- 16,628,216 64,000
Amortization of
intangible
assets 5,803,422 482,312 14,450,896 808,017
Gain (loss) on
disposition of
fixed assets (44,612) -- 203,904 --
In-process research
& development -- -- 294,800,000 --
1999 reorganization
and 1998 sale of
manufacturing
operations -- 255,701 (38,391) 255,701
Total operating
expenses 19,930,314 4,546,121 352,798,776 17,086,355
Net loss from
operations (19,650,558) (3,740,021) (351,775,207) (13,874,495)
Interest and
other income 741,641 308,513 1,905,893 1,926,090
Interest expense (215,948) (46,605) (481,310) (161,385)
Total other
income 525,693 261,908 1,424,583 1,764,705
Net loss $(19,124,865) $(3,478,113) $(350,350,624) $(12,109,790)
Accretion and
repurchase costs
on Series 1998/A
Preferred Stock -- -- -- (2,395,559)
Net loss
applicable
to common
stockholders $(19,124,865) $(3,478,113) $(350,350,624) $(14,505,349)
Basic and
diluted
net loss per
common share $(0.71) $(0.32) $(19.80) $(1.36)
Weighted average
common shares
for basic and
diluted net loss
computation 26,786,175 10,868,052 17,693,996 10,681,547
CURIS, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
December 31, December 31,
2000 1999
ASSETS
Cash, cash equivalents and
marketable securities $ 75,798,610 $ 21,370,585
Property and equipment, net 7,866,591 2,130,158
Intangible assets 97,145,664 5,075,914
Other assets 1,871,125 315,634
Total assets $182,681,990 $ 28,892,291
LIABILITIES AND STOCKHOLDERS` EQUITY
Accounts payable and accrued expenses $ 7,741,465 $ 4,113,994
Debt and capital lease obligations 6,126,759 1,356,711
Total liabilities 13,868,224 5,470,705
Total stockholders` equity 168,813,766 23,421,586
Total liabilities and
stockholders` equity $182,681,990 $ 28,892,291
--------------------------------------------------------------------------------
Contact:
Curis, Inc.
George Eldridge
(617) 503-6515
or
Cynthia Clayton
(617) 503-6641
Cris
neuigkeiten zu chondrogel!! Phase 3
die klitsche is nur noch 155mille wert.
oh,oh,oh
neuigkeiten zu chondrogel!! Phase 3
die klitsche is nur noch 155mille wert.
oh,oh,oh
Hoher Umsatz in Frankfurt !
Weiss jemand mehr ?
Weiss jemand mehr ?
Curis Begins Phase I Clinical Study With Vascugel in Coronary Artery Disease
Read this: if it hits it could be very big!!
CAMBRIDGE, Mass.--(BW HealthWire)--March 28, 2001--Curis, Inc. (NASDAQ: CRIS) today announced the initiation of a Phase I clinical trial in the U.S. with Vascugel, a cellular transplant product, in patients undergoing coronary artery bypass graft (CABG) surgery.
Vascugel is being developed to prevent complications related to cardiovascular surgical procedures and maintain long-lasting blood flow and tissue perfusion. The conditions leading to such complications include thrombosis (blockage of the blood vessel due to the formation of blood clots) and restenosis (the re-blockage of the blood vessel after surgery due to uncontrolled smooth muscle cell growth).
"CABG patients are the first population being tested for Vascugel, and we expect to evaluate additional patient populations as we move this exciting product forward," said Doros Platika, M.D., president and chief executive officer of Curis, Inc. "There are over 1.5 million revascularization procedures each year with a market opportunity of approximately $1.5 billion."
"We are very enthusiastic about the potential of this technology to reduce anastomotic complications following coronary bypass procedures," said Dr. David Adams who is the principal investigator currently enrolling patients at the Brigham and Women`s Hospital in Boston, Massachusetts. Additional hospitals are being explored as clinical sites for this trial.
"Vascugel is designed to restore the normal control function of endothelial cells after vascular injury, such as that experienced in surgery, by delivering multiple agents required to prevent thrombosis and restenosis," said Andrew C. G. Uprichard, M.D., F.R.C.P., chief operating officer of Curis, Inc. Although surgical procedures to correct these conditions are generally successful on a short-term basis, approximately 10 to 15 percent of these procedures fail within months, requiring additional intervention with further risk.
"An innovative, cell-based product such as Vascugel, which is thought to be capable of delivering multiple biochemical agents in a physiologically regulated fashion, represents a significant potential therapeutic option in connection with coronary surgery," said Dr. Uprichard. "Furthermore, because the cells used in Vascugel are allogeneic, that is, derived from an individual other than the patient, the manufacturing process is simplified and the product can be used in many patients, making it cost-effective."
Vascugel is a biodegradable implant containing human endothelial cells which, in this trial, will be wrapped at the junction (anastomosis) of the bypassed and grafted coronary blood vessels at the time of CABG procedures. The technology of wrapping endothelial cells around the outside of a blood vessel is unique and was originally conceived in Dr. Elazer Edelman`s laboratory at the Massachusetts Institute of Technology. Endothelial cells normally line the interior of the artery and are essential in controlling the proliferation of the underlying smooth muscle cells in the wall of the artery. Additional preclinical development studies performed at Curis were funded in part by an award from the National Institute of Standards and Technology.
Vascugel is believed to provide multiple biochemicals that are normally secreted by endothelial cells in response to vessel injury. These biochemicals, which include heparan sulfate proteoglycan (HSPG) and prostacyclin, are believed to control the overgrowth of smooth muscle cells lining the inside of the blood vessel and to prevent the formation of blood clots.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of Curis` Registration Statement filed on Form S-1 with the Securities and Exchange Commission and dated December 20, 2000 and Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on December 6, 2000.
CONTACT:
Curis, Inc.
Read this: if it hits it could be very big!!
CAMBRIDGE, Mass.--(BW HealthWire)--March 28, 2001--Curis, Inc. (NASDAQ: CRIS) today announced the initiation of a Phase I clinical trial in the U.S. with Vascugel, a cellular transplant product, in patients undergoing coronary artery bypass graft (CABG) surgery.
Vascugel is being developed to prevent complications related to cardiovascular surgical procedures and maintain long-lasting blood flow and tissue perfusion. The conditions leading to such complications include thrombosis (blockage of the blood vessel due to the formation of blood clots) and restenosis (the re-blockage of the blood vessel after surgery due to uncontrolled smooth muscle cell growth).
"CABG patients are the first population being tested for Vascugel, and we expect to evaluate additional patient populations as we move this exciting product forward," said Doros Platika, M.D., president and chief executive officer of Curis, Inc. "There are over 1.5 million revascularization procedures each year with a market opportunity of approximately $1.5 billion."
"We are very enthusiastic about the potential of this technology to reduce anastomotic complications following coronary bypass procedures," said Dr. David Adams who is the principal investigator currently enrolling patients at the Brigham and Women`s Hospital in Boston, Massachusetts. Additional hospitals are being explored as clinical sites for this trial.
"Vascugel is designed to restore the normal control function of endothelial cells after vascular injury, such as that experienced in surgery, by delivering multiple agents required to prevent thrombosis and restenosis," said Andrew C. G. Uprichard, M.D., F.R.C.P., chief operating officer of Curis, Inc. Although surgical procedures to correct these conditions are generally successful on a short-term basis, approximately 10 to 15 percent of these procedures fail within months, requiring additional intervention with further risk.
"An innovative, cell-based product such as Vascugel, which is thought to be capable of delivering multiple biochemical agents in a physiologically regulated fashion, represents a significant potential therapeutic option in connection with coronary surgery," said Dr. Uprichard. "Furthermore, because the cells used in Vascugel are allogeneic, that is, derived from an individual other than the patient, the manufacturing process is simplified and the product can be used in many patients, making it cost-effective."
Vascugel is a biodegradable implant containing human endothelial cells which, in this trial, will be wrapped at the junction (anastomosis) of the bypassed and grafted coronary blood vessels at the time of CABG procedures. The technology of wrapping endothelial cells around the outside of a blood vessel is unique and was originally conceived in Dr. Elazer Edelman`s laboratory at the Massachusetts Institute of Technology. Endothelial cells normally line the interior of the artery and are essential in controlling the proliferation of the underlying smooth muscle cells in the wall of the artery. Additional preclinical development studies performed at Curis were funded in part by an award from the National Institute of Standards and Technology.
Vascugel is believed to provide multiple biochemicals that are normally secreted by endothelial cells in response to vessel injury. These biochemicals, which include heparan sulfate proteoglycan (HSPG) and prostacyclin, are believed to control the overgrowth of smooth muscle cells lining the inside of the blood vessel and to prevent the formation of blood clots.
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at http://www.curis.com.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of Curis` Registration Statement filed on Form S-1 with the Securities and Exchange Commission and dated December 20, 2000 and Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on December 6, 2000.
CONTACT:
Curis, Inc.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,29 | |
| -3,52 | |
| -0,68 | |
| +0,81 | |
| -0,08 | |
| -0,22 | |
| -1,85 | |
| -1,33 | |
| -1,35 | |
| -0,09 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 164 | ||
| 101 | ||
| 60 | ||
| 55 | ||
| 47 | ||
| 39 | ||
| 39 | ||
| 38 | ||
| 37 | ||
| 33 |
